United Therapeutics Corporation (UTHR) : United Therapeutics Corporation (UTHR) had a healthy money flow of $0.24 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $0.9 million, whereas, investors only sold shares worth $0.66 million on downticks. The stock closed the day with an up-down ratio of 1.36.The money flow in the block trades to the tune of $0 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0 million worth of transactions were on upticks. United Therapeutics Corporation (UTHR) stock slid $0.68 intraday and traded at 122.54, a change of -0.55% over previous days close. However, for the week, the company shares are 0.64% compared to previous weeks close.
The company Insiders own 7.5% of United Therapeutics Corporation shares according to the proxy statements.
In a related news, The Securities and Exchange Commission has divulged that Rothblatt Martine A, director officer (Chairman & CEO) of United Therapeutics Corp, had unloaded 1,257 shares at an average price of $122.97 in a transaction dated on September 1, 2016. The total value of the transaction was worth $154,573.
United Therapeutics Corporation (NASDAQ:UTHR): stock was range-bound between the intraday low of $121.58 and the intraday high of $123.49 after having opened at $123.36 on Fridays session. The stock finally closed in the red at $123.36, a loss of -0.24%. The stock remained in the red for the whole trading day. The total traded volume was 442,952 shares. The stock failed to cross $123.49 in Fridays trading. The stocks closing price on Thursday was $123.21.
United Therapeutics Corporation (UTHR) has been under a strong bear grip, hence the stock is down -1.75% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.44% in the past 1 week. The stock has risen by 0.94% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.88% in the past 4 weeks.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.